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Reply to the Editor: 
We also recognize the importance of maintammg the 
integrity of the clavicle with its articulation with the manubri-
um and its muscular insertions. Spaggiari and Pastorino con-
cluded that our method does not maintain the integrity of the 
clavicle because there was insufficient fixation in 3 of our 5 
cases. However, they were the early cases. Our problem in the 
early period lay in the method of fixing the sectioned clavicle. 
However, besides gaining some technical experience, we 
solved the problem by fixing the clavicle with a new material, 
slightly thicker titanium plates. No problems at all have been 
encountered in the 2 most recent cases. The patients are even 
bowling with the arm on the side of the operation. 
Section of the manubrium is also possible with our method. 
When performed, it would probably be done by the ordinary 
thoracic approach. Spaggiari and Pastorino have stated that 
our method and their method are completely different proce-
dures. Although we also considered the procedure from a 
totally different viewpoint, when we evaluated the matter 
thoroughly, it seemed reasonable to conclude that our method 
is also a TMA. 
The main portion of our report says that "sectioning the 
clavicle in the TMA makes it possible to enlarge the field of 
vision and at the same time maintain clavicle integrity." An 
approach to a fairly large portion of the great vessels in the 
thoracocervical area may very well be possible without sec-
tioning the clavicle if the procedure is performed carefully. 
However, the field of vision obtained by sectioning the clavi-
cle makes it possible to visualize the great vessels in the tho-
racocervical area frontally in a way that cannot be compared 
with the exposure available when the clavicle is not sec-
tioned. The field of vision must be enlarged if the operation is 
to be performed safely. 
Takamasa Onuki, MD 
First Department of Surgery 
Tokyo Women's Medical University 
8-1 Kawada-chou Shinjuku-ku 
Tokvo 162-8666, Japan 
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Homograft valve failure in children 
To the Editor: 
We read with interest the article by Rajani, Mee, and 
Ratliff.l Their finding of a lymphocytic infiltrate associated 
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with rapid failure of cryopreserved homografts in infants 
lends support to the hypothesis of an immunologic injury 
being at least partially responsible for this failure. This con-
curs with our own clinical2 and laboratory3 findings but is not 
supported by others.4 
Rajani, Mee, and Ratliff end their article with speculation 
about the possible use of tissue matching and immunosup-
pression in these patients. Although we believe that there is 
evidence for an immunologic component to this accelerated 
failure, we would caution against the empiric use of immuno-
suppression in these children without further controlled stud-
ies. In a small pilot study we transplanted cryopreserved aor-
tic valve grafts into 21 outbred rats as previously described3 
and randomly assigned 11 to receive oral cyclosporine (10 
mg/kg per day) (INN: ciclosporin) for 56 days while the 
remaining 10 received a placebo. The striking finding of this 
study was that only 3 of the 11 grafts in the cyclosporine-
treated group remained patent at 8 weeks whereas 8 of 10 in 
the placebo group were patent (P = .03, Fisher's exact test). 
The patent cyclosporine grafts did have less medial necrosis 
and perivascular inflammation than control grafts. The cause 
of this high occlusion rate in the cyclosporine-treated group is 
unknown but may be due to a direct toxic effect of 
cyclosporine on the endothelium of these small grafts.5 
Whether the same effect would occur in larger grafts is 
unknown. 
It is likely that these avascular cryopreserved grafts fail by 
mechanisms of rejection that are substantially different from 
those affecting vascularized whole organs. Thus directly 
transferring immunosuppressive regimens used successfully 
for cardiac or renal transplantation may not be appropriate. 
We postulate that there is an immune-mediated attack on 
these grafts that damages their structural elements, making 
them more susceptible to early degeneration. Much more 
work is required to determine if this indeed is the case and to 
determine how best to minimize this response. We do not 
believe that sufficient data are yet available to recommend 
immunosuppression in children requiring homograft valves. 
David B. Ross, MD 
Gillian R. Hamilton, BA 
James R. Wright, Jr., MD, PhD 
Timothy D. G. Lee, PhD 
Division of Cardiovascular Surgery 
1WK Grace Hospital for Children 
PO Box 3070 
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Effect of normoxic cardiopulmonary bypass on 
leukocyte elastase release 
To the Editor: 
We read with great interest the recent paper by Ihnken and 
coworkers l about the reduction of oxygen-derived free radi-
cals and nitric oxide by normoxic cardiopulmonary bypass 
(CPB). In their article, the authors showed that normoxic 
CPB reduced release of neutrophil elastase in patients under-
going cardiac operations. They wrote, "this is the first time 
that a Po2-dependent elastase release on CPB is described." 
Recently, we have undertaken a prospective study on 60 
patients undergoing cardiac operations to compare the effi-
ciency and safety of different membrane oxygenators. A large 
variation in P02 appeared during perfusion, which gave us an 
opportunity to assess whether elastase release during CPB 
was dependent on the level of Po2. During CPB, arterial P02 
was measured 5 times: at the start of cooling, during cooling 
down to 32°C, on stabilized hypothermia at 28°C, during 
rewarming to 32°C, and at the end of CPB. Elastase was mea-
sured before and at the end of CPB from blood samples taken 
from the radial artery using the same method that Ihnken and 
associates described (enzyme-linked immunosorbent assay; 
Merck, Darmstadt, Germany). Results showed that P02 varied 
between 107 and 440 mm Hg at the start of cooling and 
between 80 and 308 mm Hg on stabilized hypothermia dur-
ing CPB. On an average ofthe 5 time points during CPB, P02 
varied between 128 and 317 mm Hg. Elastase increased in 
the majority of patients at the end of CPB with a concentra-
tion ranging between 41 to 490 ng/mL, or a percentage 
increase (release) of 47% to 742% compared with baseline 
concentration before CPB. However, there was no correlation 
either between P02 and elastase concentration at the end of 
CPB or between P02 and the percentage increase compared 
with the baseline elastase (Fig 1). 
Our results suggest that systemic elastase release during 
CPB is not dependent on Po2. For years, elastase release dur-
ing CPB has been known to be largely attributed to blood 
interaction with the artificial surface of the extracorporeal cir-
cuit.2•3 Modification of the material surface of the circuit has 
been associated with a reduction in elastase release either 
during clinical CPB4 or in a simulated model of CPB.5 It 
could well be that normoxic CPB had reduced the cardiac 
source of elastase but that the effect had been systematically 
counteracted by other factors, such as blood-material interac-
tion. Thus whether P02 plays a role in controlling local or 
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Fig 1. Scattergrams showing no relationship between arteri-
al P02 and systemic elastase concentration determined at the 
end of CPB (A) or the percentage increase at the end of CPB 
compared with the baseline elastase (B). P02 is the average of 
5 blood gas samples determined during CPB (see text for 
details). 
systemic elastase release is of interest, but needs to be con-
firmed by later studies as normoxic CPB becomes more 
prevalent than hyperoxic CPB. 
Y. John Gu. MD, PhD 
Piet W. Boonstra, MD, PhD 
Willem van Oeveren, PhD 
Blood Interaction Research 
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